Odette S Reifsnider (Odette Reifsnider)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Topics

Cross Sectional

Glycemic Control

Palliative Care

Top Venues

Journal of the American Heart Association

Diabetes, obesity & metabolism

BMJ open diabetes research & care

ESC heart failure

This page only lists publications with an associated author ORCID identifier.

Publications

Odette S Reifsnider, Ali Tafazzoli, Stephan Linden, Jack Ishak, Pal Rakonczai, Matthew Stargardter, Effie Kuti
Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States. Journal of the American Heart Association 13 (4) (2024)
Odette S Reifsnider, Ali Tafazzoli, Stephan Linden, Jack Ishak, Pal Rakonczai, Matthew Stargardter, Effie Kuti
Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States. Journal of the American Heart Association (2024)
Odette S Reifsnider, Ali Tafazzoli, Stephan Linden, Jack Ishak, Pal Rakonczai, Matthew Stargardter, Effie Kuti
Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States. Journal of the American Heart Association 13 (4) (2024)
Odette S Reifsnider, Ali Tafazzoli, Stephan Linden, Jack Ishak, Pal Rakonczai, Matthew Stargardter, Effie Kuti
Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States. Journal of the American Heart Association 13 (4) (2024)
Odette S Reifsnider, Ali Tafazzoli, Stephan Linden, Jack Ishak, Pal Rakonczai, Matthew Stargardter, Effie Kuti
Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States. Journal of the American Heart Association 13 (4) (2024)
Odette S Reifsnider, Ali Tafazzoli, Stephan Linden, Jack Ishak, Pal Rakonczai, Matthew Stargardter, Effie Kuti
Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States. Journal of the American Heart Association 13 (4) (2024)
Odette S Reifsnider, Ali Tafazzoli, Stephan Linden, Jack Ishak, Pal Rakonczai, Matthew Stargardter, Effie Kuti
Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States. Journal of the American Heart Association 13 (4) (2024)
Odette S Reifsnider, Pratik Pimple, Sarah Brand, Evelien Bergrath Washington, Sharash Shetty, Nihar R Desai
Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States. Diabetes, obesity & metabolism 24 (4) (2022)
Odette S Reifsnider, Anuraag R Kansal, Pranav K Gandhi, Lael Cragin, Sarah B Brand, Egon Pfarr, Kyle Fahrbach, Anastasia Ustyugova
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ open diabetes research & care 9 (1) (2021)
Odette S Reifsnider, Anuraag Kansal, Pratik Pimple, Valerie Aponte-Ribero, Sarah Brand, Sharash Shetty
Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States. Diabetes, obesity & metabolism 23 (3) (2020)
Odette S Reifsnider, Anuraag R Kansal, Jennifer Franke, Joseph Lee, Jyothis T George, Martina Brueckmann, Stefan Kaspers, Sarah B Brand, Anastasia Ustyugova, Stephan Linden, Matthew Stargardter, Nikco Hau
Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure. ESC heart failure (2020)